Basal Cell Carcinoma News and Research

RSS

Basal cell cancer begins in the lowest layer of the epidermis, the basal cell layer. About 8 out of 10 skin cancers are basal cell carcinomas. They usually begin on areas exposed to the sun, such as the head and neck. Basal cell carcinoma was once found mostly in middle-aged or older people. But now it is also being seen in younger people. This may be because people are spending more time in the sun without protecting their skin.

Basal cell carcinoma tends to grow slowly. It is very rare for a basal cell cancer to spread to distant parts of the body (metastasize). But if it is not treated, it can grow into nearby areas and spread into the bone or other tissues beneath the skin.

After treatment, basal cell carcinoma can come back (recur) in the same place on the skin. New basal cell cancers can also start in other places on the skin. As many as half of the people who have one basal cell cancer will get a new skin cancer within 5 years.

Austrian scientists challenge the clinical relevance of the term “basal-like” breast cancer subtype

Not all breast cancers are the same. Different types can mean different prognoses for the patient, and a different kind of treatment may be adequate. But how to classify tumors? Are molecular classification methods reliable? Mohammad Ali Lavasani and Farid Moinfar from the Unit of Breast and Gynecologic Pathology at the Medical University of Graz, Austria give a critical review of the literature with focus on “basal-like” carcinoma.

11 Apr 2012

Electronic pathology report more accurately identifies nonmelanoma skin cancer

Henry Ford Hospital dermatology researchers are urging caution about using claims data for identifying nonmelanoma skin cancer, suggesting that the commonly used method, which previously had not been validated, may be unreliable.

6 Apr 2012

Hedgehog and mTOR pathway are active in esophageal cancer

Identification of a non-traditional pathway for spiriting a cancer-promoting protein into the cell nucleus points to a possible combination therapy for esophageal cancer and indicates a mechanism of resistance for new drugs that attack the Hedgehog pathway.

20 Mar 2012

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

The German- Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to initiate a clinical phase I trial for Limtop. Limtop is an innovative formulation of an immunomodulatory compound with potential to treat actinic keratosis, genital warts and basal cell carcinoma.

11 Mar 2012

IDS, AADA disappointed in postponement of vote by Idaho on indoor tanning bed legislation

The Idaho Dermatology Society (IDS) and the American Academy of Dermatology Association (AADA) are disappointed in the postponement of the vote by the Idaho House of Representatives on House Bill 486, which would ban the use of indoor tanning beds by minors under the age of 18.

5 Mar 2012

Genentech receives FDA approval for Vismodegib to treat skin cancer

A new skin cancer drug tested for the first time in the world five years ago at the Virginia G. Piper Cancer Center at Scottsdale Healthcare just received expedited approval by the U.S. Food and Drug Administration, a remarkable accomplishment in new drug development.

2 Feb 2012

Roche’s skin cancer drug Erivedge gets FDA nod

The Food and Drugs Administration (FDA) this Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.

31 Jan 2012

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer.

20 Jan 2012

Live interactive consultations can improve clinical outcomes for patients

UC Davis Health System dermatologists, using videoconferencing technology known as teledemedicine, have determined that live interactive consultations can improve clinical outcomes for patients because they usually involve beneficial changes in medical diagnosis and disease management that otherwise might not occur.

19 Jan 2012

Tanning beds raise risk of skin cancer – kids need to be barred

The issue regarding the banning of under-18s from tanning beds has come up again. Manitoba MP James Bezan is pushing for it. The Conservative MP introduced a private members’ bill Thursday that would bar anyone under the age of 18 from using a tanning bed, as well as require tanning salons to improve the warning signs and labels on and around their machines.

18 Dec 2011

Women with non-melanoma skin cancers more likely to have smoked cigarettes

Women who have non-melanoma skin cancers are more likely to have smoked cigarettes compared to women without skin cancer, said researchers at Moffitt Cancer Center in Tampa, Fla., who published study results in a recent issue of Cancer Causes & Control.

9 Dec 2011

Certain IBD patients at increased risk of skin cancer

Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD.

21 Nov 2011

Radon exposure may increase risk of non-melanoma skin cancer

A new study published this week suggests that a link may exist between radon exposure and non-melanoma skin cancer.

15 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

Coffee may protect against a slow growing skin cancer: Study

A new study shows that drinking coffee was associated with decreased risk of a common and slow-growing form of skin cancer called basal cell carcinoma.

25 Oct 2011

DFMO appears to protect against nonmelanoma skin cancers

An antiparasitic agent used to treat African sleeping sickness might someday be used to prevent nonmelanoma skin cancers. Researchers found that DFMO, or α-difluoromethylornithine, still appeared to protect against nonmelanoma skin cancers years after people stopped taking the drug, according to a poster presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011.

24 Oct 2011

AAD applauds California for prohibiting indoor tanning device use among youngsters

Today California Governor Edmund G. Brown signed a bill into law that will prohibit the use of indoor tanning devices for all Californians under the age of 18.

10 Oct 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC for whom surgery is inappropriate.

12 Sep 2011

Basal Cell Carcinoma News and Research

Further Reading

Austrian scientists challenge the clinical relevance of the term “basal-like” breast cancer subtype

Electronic pathology report more accurately identifies nonmelanoma skin cancer

Hedgehog and mTOR pathway are active in esophageal cancer

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

IDS, AADA disappointed in postponement of vote by Idaho on indoor tanning bed legislation

Genentech receives FDA approval for Vismodegib to treat skin cancer

Roche’s skin cancer drug Erivedge gets FDA nod

FDA approves Genentech's Erivedge for treatment of BCC

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

Live interactive consultations can improve clinical outcomes for patients

Tanning beds raise risk of skin cancer – kids need to be barred

Women with non-melanoma skin cancers more likely to have smoked cigarettes

Certain IBD patients at increased risk of skin cancer

Radon exposure may increase risk of non-melanoma skin cancer

FDA accepts Genentech's vismodegib NDA for review

Coffee may protect against a slow growing skin cancer: Study

DFMO appears to protect against nonmelanoma skin cancers

AAD applauds California for prohibiting indoor tanning device use among youngsters

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Latest News